Chimeric proteins resulting from characteristic chromosomal translocations are believed to play a key role in the development of neoplasia. The consistent chromosomal translocation t(12;22) found in Clear Cell sarcoma (CCS) fuses the genes for Ewing's sarcoma protein (EWS) and activating transcription factor 1 (ATF1). Contribution of the chimeric EWS/ATF1 protein to maintenance of the tumor phenotype was investigated using intracellular expression of an inhibitory anti-ATF1 single chain antibody fragment (scFv4). Transfection of scFv4 into a cell line (SU-CCS-1) derived from CCS resulted in a 90% reduction in cyclic AMP response element-driven reporter activity. The delivery of scFv4 into SU-CCS-1 cells by a Moloney sarcoma retroviral vector (SR␣-Fv4) significantly reduced viability and induced apoptosis as measured by terminal deoxynucleotidetransferase-mediated dUTP-biotin nick end labeling and flow cytometry. Conversely, scFv4 had no effect on viability of HeLa cells. The level of EWS/ATF1 expression was found to be significantly higher in primary tumor tissue than in SU-CCS-1 cells or in 293T cells following introduction of an EWS/ATF1 expression vector. These studies demonstrate a direct role for the EWS/ ATF1 fusion protein in maintaining tumor cell viability of Clear Cell sarcoma and indicate that intracellular antibodies may be used to achieve a phenotypic knockout of tumor-related proteins as a method to explore their function.
Chimeric proteins resulting from characteristic chromosomal translocations are believed to play a key role in the development of neoplasia. The consistent chromosomal translocation t(12;22) found in Clear Cell sarcoma (CCS) fuses the genes for Ewing's sarcoma protein (EWS) and activating transcription factor 1 (ATF1). Contribution of the chimeric EWS/ATF1 protein to maintenance of the tumor phenotype was investigated using intracellular expression of an inhibitory anti-ATF1 single chain antibody fragment (scFv4). Transfection of scFv4 into a cell line (SU-CCS-1) derived from CCS resulted in a 90% reduction in cyclic AMP response element-driven reporter activity. The delivery of scFv4 into SU-CCS-1 cells by a Moloney sarcoma retroviral vector (SR␣-Fv4) significantly reduced viability and induced apoptosis as measured by terminal deoxynucleotidetransferase-mediated dUTP-biotin nick end labeling and flow cytometry. Conversely, scFv4 had no effect on viability of HeLa cells. The level of EWS/ATF1 expression was found to be significantly higher in primary tumor tissue than in SU-CCS-1 cells or in 293T cells following introduction of an EWS/ATF1 expression vector. These studies demonstrate a direct role for the EWS/ ATF1 fusion protein in maintaining tumor cell viability of Clear Cell sarcoma and indicate that intracellular antibodies may be used to achieve a phenotypic knockout of tumor-related proteins as a method to explore their function.
Characteristic chromosomal translocations are commonly present in specific types of mesenchymal tumors and frequently involve genes encoding transcription factors (1) (2) (3) . The clonal nature of these chromosomal abnormalities, their association with specific cell types, and their presence in somatic cells but not germ cells suggests an important role in the development of neoplasia. Transcription factors are typically composed of multiple domains with different functions including DNA binding, dimerization, and transcriptional activation. The combination of specific domains from unrelated transcription factors may result in the generation of chimeric proteins with activity distinct from either of its components (3) .
The chromosomal translocation t(12;22)(q13;q12) associated with Clear Cell sarcoma (CCS) 1 was first described by Bridge et al. (3, 4) and has since been shown to be a characteristic finding of diagnostic value. The balanced translocation gives rise to a fusion protein in which the N-terminal 325 amino acids of the Ewing's sarcoma protein (EWS) replace the N-terminal 65 amino acids of the activating transcription factor 1 (ATF1) (3, 4) . The reciprocal ATF1/EWS translocation does not produce a fusion product in transformed cells due to the presence of an in-frame stop codon immediately C-terminal to the ATF1 sequence. The biologic role of EWS is not well understood. EWS functions as an RNA-binding protein and may play a role in RNA processing (5) . Bertolotti et al. (6) suggested EWS may also function as a transcription factor due to a high degree of homology with the TBP-associated factor hTAF II 68. EWS was shown in studies by Pan et al. (7) to possess multiple determinants that cooperate synergistically to activate transcription, but by itself EWS was not capable of binding to DNA. Proteinprotein interactions may occur between transcription factors, independent of DNA binding, and are important in transcriptional activation. EWS also participates in fusion proteins with other DNA-binding proteins, most notably FLI (8) , a member of the ETS family, and EWS/FLI is overexpressed in Ewing's sarcoma. ATF1 is a member of the CREB/ATF subfamily of bZIP transcription factors that also includes CREB and CREM (9 -11) . These inducible transcription factors regulate transcription through binding as homodimers or heterodimers to cyclic AMP response elements (CRE) following activation of certain pathways such as protein kinase A. ATF1 is a weaker transactivator in vitro than CREB (12, 13) . EWS/ATF1 is predicted to bind to CREs via the bZIP domain provided by the C-terminal region of ATF1, but it does not retain cAMP-inducible activation due to partial deletion of the kinase-inducible domain located in the N-terminal 65 amino acids of ATF1 (14) .
Brown et al. (15) have shown in a heterologous cell type that EWS/ATF1 is a strong constitutive activator of some CREcontaining promoters and a repressor of others. A plausible mechanism for transformation in Clear Cell sarcoma involves the deregulated activation of CRE-containing promoters by the fusion protein. Other chimeric proteins, including the PAX/ FKHR chimeric protein found in rhabdomyosarcoma, are capable of transforming cells in culture, and EWS/ATF1 may func-tion in a similar manner to initiate tumor cell proliferation (16) . The development of cancer is believed to be a multistep process, and downstream events may occur that render the tumor independent of the initiating event (14) . It is not known whether EWS/ATF1 or other chimeric proteins resulting from translocations are essential for maintenance of cell proliferation.
In studies aimed at addressing the cellular roles of ATF1, a single chain Fv fragment (scFv) was derived from an anti-ATF1 monoclonal antibody (mAb). The mAb, designated mAb41.4, inhibited ATF1 binding and transcriptional activation from CRE-containing promoters in vitro, and its epitope was mapped to the first 15 residues N-terminal to the DNA binding domain (13, 17) . The single chain variable fragment (scFv) derived from mAb41.4 (designated scFv4) retained in vitro activity, but unlike the mAb, it could be expressed intracellularly to target ATF1 activity (18) . The availability of the anti-ATF1 scFv4 provided a unique means to explore the importance of DNA binding by EWS/ATF1 and evaluate its role in the neoplastic process. In this study, we demonstrate that the C-terminal region of EWS/ATF1 retains the mAb4 epitope and that this epitope is accessible for binding by scFv4. In electrophoretic mobility shift assays (EMSA), the presence of mAb4 was capable of inhibiting CRE binding by EWS/ATF1. Intracellular expression of scFv4 reduced the activational effect of EWS/ATF1 on CRE-containing reporters when transfected into HeLa cells expressing EWS/ATF1 but had no effect on cell viability. Additional studies were performed in 293T cells transfected with EWS/ATF1 and in a cell line termed SU-CCS-1, derived from a human CCS tumor. Levels of EWS/ATF1 in both of these cell lines were lower than the level of EWS/ATF1 in primary tumor tissue as determined by Western blot. Following transfection into the EWS/ATF1-expressing SU-CCS-1 cell line, scFv4 reduced activity of a CRE-containing reporter, and this inhibitory effect could be reversed by overexpression of ATF1. These studies suggested that the role of EWS/ATF1 in maintenance of the malignant phenotype could be investigated directly if scFv4 intracellular expression could be achieved in a high percentage of SU-CCS-1 cells. When introduced via retroviral vector into SU-CCS-1 cells, intracellular expression of scFv4 reduced viability to 10% compared with controls. Evidence of tumor cell death occurring through an apoptotic mechanism was obtained by TUNEL and flow cytometry.
MATERIALS AND METHODS
Preparation of mAbs and scFv-Preparations of mAb4 were affinity purified on a protein G column and quantitated by absorbance at 280 nm (assuming 1 mg IgG/ml of IgG ϭ 1.4 A 280 ) with the Bradford assay (Bio-Rad). Soluble scFv4 was produced and quantitated as described previously (38) . Escherichia coli HB21 cells, incubated until reaching an A 600 of 0.6, were induced with isopropyl-D-thiogalactopyranoside and incubated an additional 4 h at 25°C. The periplasm was extracted in a high salt lysate buffer, clarified, and dialyzed. scFv4 quantitation was performed through slot blotting of the periplasmic extract and a peptide standard. The slot blots were stained with an anti-c-myc tag Ab (murine 9E10 hybridoma, ATCC) and an alkaline phosphatase (AP)-conjugated anti-mouse IgG heavy and light (H & L) chain Ab (Jackson ImmunoResearch Laboratories, West Grove, PA). A standard curve (1-100 ng) using c-Myc peptide 1 (Oncogene Research Products, Cambridge, MA) was generated, and the signal of scFv wells was visually compared for determination of approximate concentration and digitally scanned for densitometric analysis. Following normalization for mass (mass of cMyc peptide ϭ mass of scFv/8), the average periplasmic concentration of scFv was observed to be 5 ng/ml.
Reverse Transcriptase-Polymerase Chain Reaction and Isolation of EWS/ATF1 cDNA-Total RNA mini-preps were prepared from 100-mm dishes of SU-CCS-1 cells using Qiagen RNeasy and QuiaShredder columns (Qiagen, Valencia, CA). The protocol for the isolation of total RNA from animal cells was followed as supplied by the manufacturer. 50 ng of total RNA was reverse-primed with an oligonucleotide poly(dT) primer and extended with Superscript TM reverse transcriptase (Life Technologies, Inc.) according to established protocols.
The EWS/ATF1 (15) fusion was amplified from the product of the cDNA synthesis by polymerase chain reaction with appropriately designed primers based on the GenBank TM ATF1 and EWS sequences. A polymerase chain reaction product of approximately 1600 base pairs was obtained and ligated into the T/A cloning vector (Invitrogen, Carlsbad, CA) for screening and sequencing. Multiple colonies were screened using mini-prep spin columns (Qiagen), and those containing the properly sized insert were submitted for automated sequencing.
DNA Constructs-For intracellular expression assays, the cDNA of EWS/ATF1 was cloned into pCMV4 (18) . The EcoRI-HindIII fragment from T/A-EWS/ATF1 was inserted into the BglII-HindIII sites of pCMV4 to generate the vector referred to as pEWS/ATF1 and used to generate protein in 293T cells. The vectors pATF1 and pFv4 are as described previously (18) . The EWS/ATF1 cDNA was inserted into the EcoRI site of pET29(b) (Novagen, Madison, WI) which had the NcoIEcoRV fragment removed. This construct, pET-EWS/ATF1, was screened for orientation and used for the in vitro generation of recombinant protein in E. coli BL21.
Preparation of Recombinant Proteins-Recombinant EWS/ATF1 was generated by in vitro transcription-translation using the TnT® T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI) as per the instructions of the manufacturer. Both 35 S-labeled and unlabeled recombinant proteins were generated for use as markers in Western blot and EMSA. Recombinant EWS/ATF1 and ATF1 were also generated through isopropyl-D-thiogalactopyranoside induction of ATF1 cDNA and EWS/ATF1 cDNA containing pET vectors in E. coli BL21 (19) . ATF1-expressing bacteria were boiled for 20 min as described previously (19) . EWS/ATF1 was isolated as the insoluble protein fraction of induced bacteria according to established protocols (20) . Additionally, EWS/ATF1 was generated in 293T cells following transfection with pEWS/ATF1 and isolation of the nuclear extract using established protocols.
Electrophoretic Mobility Shift Assays-EMSA were performed as described previously (13, 17) . Incubations were conducted at 30°C after determining that EWS/ATF1 forms more intense complexes with the CRE at this temperature. 32 P-Labeled oligonucleotide containing the consensus CRE 5Ј-AGA GAT TGC CTG ACG TCA GAG AGC TAG-3Ј was incubated with 50 ng of full-length recombinant ATF-1 from E. coli BL21 or EWS/ATF1 from 293T cells. The binding reactions were done in the presence or absence of mAb4, mAb5, EWS-N, and species and isotype-matched controls. Following electrophoresis, the bound and unbound fractions of labeled oligonucleotide were quantitated by autoradiography for 12 h using a PhosphorImager (Molecular Dynamics). The PhosphorImager data were exported as TIFF files and used to prepare Fig. 1 , B and C.
Immunoblot Assays-Protein extractions from HFF and SU-CCS-1 cell lines were made using triple detergent saline (TDS) lysis buffer (1.0% Triton X-100, 0.5% deoxycholate, and 0.1% lauryl sulfate (SDS)). Protein extraction efficiencies were determined by examining the relative amount of EWS/ATF1 and/or ATF1 in the insoluble cell membrane fraction as compared with the TDS-soluble fraction. The insoluble fraction remaining from the original TDS extraction was re-solubilized in 1% SDS, and DNA was sheared by sonication. The samples were boiled for 10 min and analyzed by SDS-polyacrylamide gel electrophoresis. Immunoblots (Western) were performed as described previously (13) . Protein extraction from a Clear Cell sarcoma tumor was performed by mechanical homogenization in the presence of TDS lysis buffer. Protein concentrations were determined for each extract using the Bradford Assay Kit (Bio-Rad). Immunoprecipitation was performed using mAb1 and mAb5 concurrently and 20 l of protein A-Sepharose (6 g/l) incubated with 150 ng of cellular or tumor extract for 150 min at 4°C. Efficiency of immunoprecipitation was determined by comparison of pre-and post-immunoprecipitation and supernatant fractions by SDSpolyacrylamide gel electrophoresis and transfer to nitrocellulose. Membranes were incubated with either 1 g/ml mAb5 followed by an alkaline phosphatase (AP)-conjugated goat anti-mouse heavy and light (H & L) chain secondary antibody (Jackson ImmunoResearch) or EWS-N (Santa Cruz Biotechnology) followed by an AP-conjugated mouse antigoat antibody (Santa Cruz Biotechnology). The stained Western blots were digitally scanned using a UMAX Astra 610s scanner to generate transfer image file format (TIFF) images that were imported into Canvas version 5.0.3 and used to prepare Fig. 1D . In vitro 35 S-labeled EWS/ATF1 analyzed by autoradiography migrated identically to the presumed EWS/ATF1 band generated by Western blot, thus confirming the identity of the EWS/ATF1 band. Analysis of band intensity was performed on the stained blots using a densitometer (Molecular Dynamics).
Transient Cotransfections and Luciferase/␤-Galactosidase Assays-
Transient cotransfections of HeLa cells were performed according to established protocols using calcium phosphate precipitation (18) . The transfections were performed in duplicate 35-mm wells containing 5 g of the CMV-luciferase reporter construct and an Rous sarcoma virus-␤-galactosidase construct (2 g) to control for variations in transfection efficiency. Cotransfections included increasing amounts of the EWS/ ATF1 vector at 0, 5, 10, and 20 g and the presence of plasmids pFv4 and pATF1. Additionally, a molar equivalent of parent vector (without cDNA insert) was used to maintain an equal number of promoter units in each transfection. The cells were harvested at 48 h post-transfection, and the reporters were assayed. Transient cotransfections of SU-CCS-1 cells were performed using a similar approach of increasing amounts of pFv4. To facilitate efficient transfection of SU-CCS-1 cells, liposomemediated transfection was used with the LipofectAMINE PLUS system (Life Technologies, Inc.), and cells were harvested at 72 h. Measurement of reporter activity of firefly luciferase was determined as described relative to an internal ␤-galactosidase standard. Following transfection, cell extracts were prepared by freeze-thaw lysis in a potassium phosphate buffer. ATP and luciferin were added, and light emission was measured with a Luminoskan RS (Lab Systems/Denley, Franklin, MA) microplate luminometer. ␤-Galactosidase expression was quantitated through the addition of o-nitrophenyl-␤-D-galactopyranoside, and the absorbance at 405 nm was measured on an enzymelinked immunosorbent assay plate reader. The luciferase value of each well was normalized to the internal ␤-galactosidase reporter. Results of three to five experiments were then averaged to generate the data depicted in Figs. 2 and 3.
Production of Retrovirus and Infection of Cells-
The retroviral vectors were produced by inserting the EcoRI-HindIII fragment of pFv4 that contains the cDNA of scFv4 into the SR␣-PN retrovirus at the corresponding sites. SR␣-PN was kindly provided by Dr. T. Smithgall and is the SR␣MStkneo vector described by the laboratory of Dr. O. Witte (21-23) with the pCMV5 polylinker inserted into the HindIII site. To infect SU-CCS-1 cells, the SR␣-Fv DNA construct was cotransfected into 293T cells with the amphotrophic packaging vector psi(Ϫ) ampho. 10 g of each was transfected using the LipofectAMINE system. The cellular supernatant was collected every 12 h between 24 and 72 h post-infection and pooled. The retroviral titer was determined by colony-forming assay in 3Y1 cells grown in minimum Eagle's medium containing 5% bovine calf serum and 800 mM G418 (Geneticin). Typical yields of retrovirus were 10 4 cfu/ml. Infection of cells was performed using 3 ml of retroviral stock/well in a 6-well plate in the presence of 4 mg/ml hexadimethrine bromide (Polybrene). Plates were spun at 1250 ϫ g in a refrigerated centrifuge at 18°C.
Cell Viability Determinations, Trypan Blue Exclusion, and MTS Assays-The viability of SU-CCS-1 cells infected by SR␣-Fv4 or control SR␣-PN was determined by trypan blue stain exclusion. Cells were harvested from 35-mm dishes with a rubber policeman, suspended in minimum Eagle's medium, and transferred to centrifuge tubes. The cells were washed in PBS and resuspended in 1 ml of PBS. An equal amount of cell suspension was added to 2ϫ trypan blue stain, and the cells were counted in a hemocytometer. Grids were counted to quantitate blue cells and white cells until a minimum of 400 was obtained. In order to avoid the mechanical harvesting which could interfere with viability measurements, an MTS assay was performed using the CellTiter 96 Aqueous non-radioactive proliferation assay (Promega) which is a colorimetric method for determining the number of viable cells in proliferation assays. The assay is composed of the tetrazolium compound 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and the electron coupling reagent phenazine methosulfate. MTS is bioreduced by cells into a formazan that is soluble in tissue culture medium. The absorbance of the formazan at 490 nm can be measured directly from 96-well assay plates without additional processing. The conversion of MTS into the aqueous soluble formazan is accomplished by dehydrogenase enzymes found in metabolically active cells. Therefore, the quantity of formazan is directly proportional to the number of living cells in culture. For this assay, SU-CCS-1 cells were plated at 2 ϫ 10 4 cells/well and infected with SR␣-Fv4 or controls (0.2 ml/well). Cell infections were conducted over 7 days to generate a time course of viability. On day 7, 96-well plates were incubated with the MTS assay reagents, and the absorbance was measured. The results of 3-6 experiments were normalized and plotted as percent viable cells versus time. The same MTS procedure was used to study the effect of SR␣-Fv4 and control treatments on HeLa cell viability over a 4-day time course.
Apoptosis Measurements, Flow Cytometry, and TUNEL Staining-50 l of the washed cell suspensions described above were plated on glass slides, air-dried, and fixed in 50% acetone, 50% methanol. The remaining cell suspension was pelleted and fixed in 70% ethanol. The ethanolfixed cells were prepared for DNA content analysis and apoptosis measurement by flow cytometry by washing in PBS and staining with propydium iodide (Telford reagent) overnight (24) . Measurements were made using a Becton Dickinson FACStar PLUS flow cytometer, and the data set was analyzed using ModFit DNA modeling software (Versity Software, Topsham, ME). The slides of fixed cells were stained for apoptosis by in situ labeling of DNA breaks using terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) (25) . TdT was used to incorporate biotinylated deoxyuridine at sites of DNA breaks, and the signal was amplified by avidin-peroxidase and photographed under light microscopy.
RESULTS

Anti-ATF1 mAbs Recognize the EWS/ATF1 Fusion Oncoprotein and Inhibit Its Binding to a CRE-EWS/ATF1
incorporates the C-terminal region of ATF1 containing the epitopes of the two anti-ATF1 mAbs used in these studies (Fig. 1A) . Although both mAb4 and mAb5 recognize epitopes adjacent to the DNA binding domain of ATF1, mAb4 interferes with DNA binding by ATF1 in EMSA, and mAb5 super-shifts ATF1 without disrupting its DNA binding activity (18) . The contribution of EWS to the overall conformation of the chimeric protein is unknown, and it was important to determine whether the addition of the EWS domain would block the epitope of mAb4 and mAb5. EWS/ATF1 and ATF1 were used in gel shift assays with radiolabeled CRE DNA to evaluate the ability of mAb4 and mAb5 to bind EWS/ATF and determine the effect of mAb4 and mAb5 on complex formation. EWS/ATF1 binding to CRE DNA has been previously demonstrated (14, 15, 26) ; however, it is not known whether CRE sequences are the primary target in cells or whether other related DNA sequences are capable of being bound (13, 17) . For these studies, a consensus CRE (TGACGTCA) as occurs in the somatostatin promoter was utilized. EWS/ATF1 was expressed in 293T cells rather than bacteria to control for possible effects of post-translational modification (13, 17) . The presence of mAb4 inhibited EWS/ATF1 complex formation (lane 5, Fig. 1C ), whereas mAb5 supershifted the EWS/ATF1 complex (lane 7). This effect on complex formation was similar to that of mAb4 on ATF1⅐CRE complexes (compare lanes 2 and 5, Fig. 1B ) and the supershift of ATF1⅐CRE complexes by mAb5 (lane 7). The EWS-N Ab (Santa Cruz Biotechnology), which recognizes the N-terminal region of EWS, was used to verify the identity of the EWS/ATF1 complex and this antibody was capable of producing a partial supershift (lane 6, Fig. 1C ). As expected, EWS-N had no effect on ATF1⅐CRE complexes (lane 6, Fig. 1B) . Specificity of EWS/ ATF1 for the CRE was demonstrated with the addition of 100-fold excess of unlabeled AP1 and CRE competitors. Competition with unlabeled CRE resulted in a loss of ATF1 complexes, whereas competition using AP1 did not diminish the intensity of the complex (lanes 3 and 4, Fig. 1, B and C) . AP1 is useful as a control for specificity since it differs from a consensus CRE by only one G-C base pair at its center. Isotypematched control Abs had no effect on complex formation (data not shown). These studies indicated that although the EWS domain is considerably larger than the deleted amino portion of ATF1, it did not interfere with binding of specific epitopes by either mAb4 or mAb5.
The EWS/ATF1 Fusion Protein Is Expressed at Greater Levels Than Endogenous ATF1-The EWS/ATF1 fusion protein is hypothesized to be the primary genetic event leading to CCS; however, the level of EWS/ATF1 expression in primary tumor tissue has not been demonstrated previously. Extracts from SU-CCS-1 cells, a primary CCS tumor, and a primary human fibroblast cell termed HHF were immunoprecipitated and analyzed by Western blotting (Fig. 1D) . Efficiencies of protein extraction and immunoprecipitation were both shown to be greater than 95% (data not shown). HHF cells were utilized to represent non-transformed control cells of mesenchymal origin. Recombinant ATF1 expressed in E. coli BL21 and EWS/ATF1 expressed in 293T cells were used as markers for the proteins of interest. The EWS-N Ab (Santa Cruz Biotechnology) which recognizes the N-terminal region of EWS was again used to confirm identity of the presumed EWS/ATF1 band. Due to the t(12;22) translocation, only one normal ATF1 allele remains in SU-CCS-1 cells and the CCS tumor (4). However, levels of ATF1 were similar to those of nontransformed HFF fibroblasts with two alleles. The EWS/ATF1 band was considerably darker in comparison with the endogenous ATF1 band in the SU-CCS-1 cell line and the CCS tumor ( lane 3 and 4, Fig. 1D ). Densitometric analysis indicated that EWS/ATF1 levels were 3.0-fold greater than those of ATF1 in the SU-CCS-1 cell extract and 10.6-fold greater than ATF1 in the CCS tumor extract. As expected, EWS/ATF1 was not present in the control HHF cell extract.
scFv4 Inhibits EWS/ATF1 Activation of a CRE Reporter in
HeLa Cells-In our past studies, inhibition of specific complex formation in vitro by mAb4 was predictive of decreased reporter expression in transfected cells (18) . Since EWS/ATF1 binding to a CRE was inhibited in vitro by mAb4, a similar effect on transactivation was expected in cells following transfection of scFv4. HeLa cells were chosen for their relatively higher level of ATF1 versus CREB expression and their well documented history of CRE reporter activation (18) . Transient cotransfection assays of HeLa cells were performed using a CRE luciferase reporter and constructs expressing scFv4 (pFv4) and EWS/ATF1 (pEWS/ATF1). The reporter construct incorporated the strong CMV immediate early gene promoter which contains five CRE sequences. To normalize results for variation in transfection efficiency between experiments, an internal Rous sarcoma virus-␤-galactosidase control was included in the transfection system.
The number of promoter elements present in each transfection was held constant by the addition of equimolar amounts of parental vectors. Transfection of 5 g of pEWS/ATF1 per 10 6 HeLa cells produced a 3.3-fold increase in CRE-luciferase expression and use of 10 g pEWS/ATF1 per 10 6 cells produced a 6.5-fold increase (Fig. 2) . Cotransfection of pFv4 (10 g per 10 6 cells) into this system reduced the observed 6.5-fold increase in reporter expression to less than 3-fold, thus suggesting that scFv4 was capable of inhibiting CRE activation by EWS/ATF1 in HeLa cells. The levels of CRE reporter expression in response to EWS/ATF1 were similar to those previously described (14, 15, 26) . Expression of EWS/ATF following transfection was confirmed using immunofluorescently labeled antibodies (data not shown).
scFv4 Inhibits the Activity of Endogenous EWS/ATF1 in SU-CCS-1 Cells-
The SU-CCS-1 cell line was derived from a CCS tumor that expresses endogenous EWS/ATF1 (27) and optimal transfection conditions were unknown. Therefore, a green fluorescent protein (GFP)-expressing construct was used to determine the optimal transfection method and time course to be used. A higher level of transfection efficiency was achieved using the liposome-mediated system than with calcium phosphate. Expression of CRE-luciferase reporter measured over a 24 -96-h time course demonstrated the peak level occurred at 72 h. Therefore, to evaluate the effect of scFv4 on endogenous EWS/ATF1 activity, transient transfections of SU-CCS-1 cells were performed using the liposome-mediated method, and luciferase activity was measured at 72 h with CRE-luciferase reporter and increasing amounts (2.5-10 g per 10 6 cells) of pFv4. Luciferase reporter activity decreased proportionately as increasing amounts of pFv4 were transfected into the SU-CCS-1 cells. Activity was reduced by 80% when 10 g of pFv4 per 10 6 cells was used (Fig. 3) . Previously, we have observed that 10 g of pFv4 per 10 6 cells decreased reporter activity by only 20% in the non-EWS/ATF1-expressing HeLa cell line (18) . Therefore, the significantly greater decrease in reporter activity in SU-CCS-1 cells was likely to be due to the inhibition of the strong EWS/ATF1 activator by scFv4 and not inhibition of endogenous ATF1 activity. However, since the decrease in CRE reporter activity was reversed by overexpression of ATF1, either possibility remained. 1 g of pATF1 cotransfected with 2.5 g of pFv4 per 10 6 SU-CCS-1 cells restored luciferase expression to near base-line levels (Fig.  3) , indicating that ATF1 competed for scFv4 binding and allowed free EWS/ATF1 or endogenous factors to activate the CRE reporter. In HeLa cells, the small effect on reporter activity may be due to the presence of other strong activating proteins that regulate expression as well as regulatory elements other than CRE. Although in vitro assays may not accurately reflect all aspects important to transcriptional regulation, the level of inhibition by scFv4 was predictive of results when cell viability was determined.
Long Term Expression of scFv4 in SU-CCS-1 Cells Leads to Loss of Cell viability and
Death-Our next goal was to deliver the scFv4 to a majority of SU-CCS-1 cells to determine whether the inhibition of EWS/ATF1 activity would affect cell viability. Earlier work with the GFP constructs demonstrated that less than 10% of the SU-CCS-1 cells were transfected by the liposome-mediated system. The ability of a Moloney sarcoma retrovirus system (SR␣MStkneo) to transduce the SU-CCS-1 cells was examined (21) (22) (23) ). An SR␣ retrovirus capable of expressing GFP demonstrated a transduction efficiency of 80% or greater (data not shown). Therefore, to attain widespread delivery of scFv4 to the SU-CCS-1 cells, the SR␣ retroviral system was utilized and modified to express scFv4. The cDNA of scFv4 was placed into the SR␣-PN construct and used to produce infectious amphotropic retrovirus. SU-CCS-1 cells were transduced with 10 4 cfu of either SR␣ retrovirus expressing scFv4 (SR␣-Fv4), the parental SR␣-PN with no insert, or a mock media preparation that simulated the infection conditions (control). The SU-CCS-1 cells were visually inspected daily following treatment. Control cells showed no decrease in density, grew to confluence, and showed no reduction in viability (Fig.  4A ). Cells exposed to SR␣-Fv4 demonstrated membrane blebbing and cell nuclear condensation beginning at day 3, and these changes subsequently became apparent throughout the population. By day 5, the cytotoxic effects reached maximum, and cell density began to decrease substantially. At day 7, viable cells were sparse and examination under ϫ 100 magnification showed considerable cellular debris (Fig. 4C) . The experiments were repeated on three occasions with similar results. Conversely, less than 1% of cells exposed to SR␣-PN demonstrated focal cytotoxic effects apparent at day 5, characterized by a reduction in cell size and focal membrane blebbing. However, the remaining cells continued to grow and proliferate to day 10 with no progressive loss in viability (Fig. 4B) .
To correlate the physical appearance of cells with an objective measurement, the percentage of viable cells was determined by two different methods as follows: trypan blue dye exclusion and the MTS assay (CellTiter AQueous 
. Photomicrographs of SU-CCS-1 cells 10 days after exposure to mock (A), SR␣-PN (B), and SR␣-Fv4 retroviral preparations (C).
beginning at day 2 which became prominent by day 5 with only one-third of the cells remaining viable. Corresponding to our visual observations, only 10% of the SU-CCS-1 cells remained viable as determined by dye exclusion at day 10 ( Fig. 5A) . Control SR␣-PN infected cells and mock-transduced cells had similar percentages of viable cells throughout the course of study. Since the levels of viability in the control cells was 60% rather than the expected 90 -100%, we investigated the effect of cell-harvesting procedures on overall viability when measured by the dye exclusion method. The impact of harvesting cells by scraping was examined by comparison of results with the MTS assay that requires minimal cell manipulation. The viability of SR␣-Fv4-transduced cells declined to 60% on day 3 and continued to decrease to 30% at day 7 as determined by MTS assay. In comparison, both the mock-transduced cells and those transduced by SR␣-PN demonstrated similar results with the percentage of viable cells starting at 100% and decreasing to 60% at day 7 (Fig. 5B) . Since the results by both trypan blue exclusion and MTS assay were similar and corresponded to the visual appearance, we concluded that the expression of scFv4 had a significant effect on SU-CCS-1 cell viability, and based on the morphologic appearance, we postulated that cell death may be occurring through a process of apoptosis.
The Intracellular Expression of scFv4 Induces Apoptosis in SU-CCS-1 Cells-The process of SU-CCS-1 cell death could occur through either necrosis or apoptosis or a combination of both mechanisms (28, 29) . The visual observations described above suggested that apoptosis was occurring in the SR␣-Fv4-infected cells. In order to confirm these observations, aliquots of SU-CCS-1 cells from the same time course as the viability study were first submitted for DNA content analysis by flow cytometry (Fig. 6A) . Differences between controls and SR␣-Fv4-infected cells were apparent at day 3 and continued to increase throughout the remainder of the 10-day time course. Transfection by SR␣-Fv4 resulted in 25% apoptosis at days 5-7 which increased to 33% on day 10. At similar time points of days 5 and 10, 15% (p Ͻ 0.05) and 18% (p Ͻ 0.00005) of the mock-transduced cells were apoptotic, respectively, and 10% (p Ͻ 0.005) and 22% (p Ͻ 0.0005) of the SR␣-PN-transduced cells were apoptotic, respectively (Fig. 6) . Although values for the measurements of apoptosis induced by SR␣-Fv4 made by flow cytometry are significantly different, the processes of harvesting, centrifugation, washing, and staining could contribute to cell damage and death. Therefore, to minimize the effect of processing on apoptosis, cells were also fixed to slides and analyzed by TUNEL (25) . SR␣-Fv4, SR␣-PN, and control cells were analyzed at days 1, 3, 5, and 10. A progressive increase in both the number and intensity of TUNEL-positive SU-CCS-1 cells following transduction by SR␣-Fv4 was apparent beginning at day 3 and became extensive between day 5 and day 10 ( Fig. 6B) . At day 10, 30% of cells were TUNEL-positive. No intensely dark-staining nuclei were observed in the control preparations at day 1.
Expression of scFv4 in HeLa Cells Does Not Alter Cell Viability-Since the intracellular expression of scFv4 could potentially induce cell death due to cross-reactivity with ATF1 or CREB, retroviral transduction experiments were performed in HeLa cells in which ATF1 and CREB are readily detectable. HeLa cells were transduced with 10 4 cfu of SR␣-Fv4, SR␣-PN, or a mock media (control) preparation and assayed by the MTS method. Although transient effects were again seen at day 1, no significant differences in cell viability were observed between the scFv4 and control treated cells (Fig. 5C ). The absence of any reduction in the percentage of cells remaining viable indicated that scFv4 is not toxic to HeLa cells and support the conclusion that apoptosis in SU-CCS-1 cells was due to specific targeting of the EWS/ATF1 fusion protein rather than the inhibition of other transcription factors.
DISCUSSION
Malignant transformation is believed to be a multistep process, and chromosomal translocations that generate chimeric proteins such as EWS/ATF1 may initiate a cascade of events leading to cancer (3, 29, 34) . The exquisite specificity of antibodies for defined targets presents numerous opportunities for disrupting protein-protein or protein-DNA interactions, particularly when the targeted structures are complex and not amenable to blockade by small molecules. Recently, scFvs have been used to achieve phenotypic knockout of cell surface or cytoplasmic target proteins involved in neoplasia such as KiRas, ErbB2, epidermal growth factor receptor, and the interleukin-2 receptor (20, (31) (32) (33) . We considered whether a similar approach could be used to disrupt activity of a nuclear protein and demonstrate its role in the neoplastic process. In SU-CCS-1 cells, interference with the activity of EWS/ATF1 could theoretically eliminate the initiating process leading to neoplasia and yet have no effect on tumor growth since other pathways may become dominant following transformation. Interference with DNA binding and transcriptional activity by the ATF1-inhibitory scFv demonstrated EWS/ATF1 is important for maintenance of tumor cell viability in addition to its previously proposed role in initiating the neoplastic process (38) . Although DNA binding was blocked, the EWS/ATF1 protein remained available for interactions with other proteins of the transcriptional apparatus (16) .
Two plausible explanations for the effect of scFv4 on EWS/ ATF1 have been considered as follows: either scFv4 inhibits DNA binding of EWS/ATF1 in the nucleus of cells or scFv4 binds to EWS/ATF1 in the cytoplasm or nucleus leading to premature degradation or immunodepletion. We believe the former mechanism is most likely as the inhibitory effect has been studied extensively in vitro, and both mAb4 and scFv4 are capable of inhibiting complex formation whether added before or after ATF1 is complexed with CRE DNA (13, 18) . As such, mAb4 could inhibit EWS/ATF1 binding through either steric or allosteric mechanisms. The predicted interactions between CRE DNA and ATF1 are based on the structural studies of GCN4 bound to CRE DNA and AP-1 DNA (35, 36) . A conformational change in a critical domain of EWS/ATF1 may occur following binding by scFv4, or presence of the antibody may destabilize the important amino acid side chain interactions with the phosphate-DNA backbone. When EWS/ATF1 is not bound to DNA, the antibody may prevent binding of transcription factor to DNA by occupying a region adjacent to the DNA binding domain. Although the binding kinetics of EWS/ATF1 are not known, scFv4 has been shown to disrupt ATF1⅐DNA complexes, and the presence of scFv4 in the region between the ␣-helices may also prevent rebinding of the factor to DNA. If immunodepletion is the mechanism, then the inhibitory effect of scFv4 on EWS/ATF1 may be due to the removal of transcription factor from the cellular pool by altering its intracellular processing or nuclear transport. Additional studies are in the process of examining the complex issue of intracellular processing of scFv4 and/or EWS/ATF1 at the single cell level.
Fujimura et al. (26) have proposed that EWS is a negative regulator of ATF1 binding activity based on relatively lower intensity of recombinant protein complexes in gel shift assays and results from deletion mutant experiments. We also noted a significant difference in the relative binding affinity of recombinant EWS/ATF1 to the CRE as compared with recombinant ATF1 when measured by band intensity on EMSA. However, the intensity of EWS/ATF1⅐CRE complexes using cellular ex-tracts from either 293T or SU-CCS-1 cells was roughly equivalent to that seen with recombinant ATF1 (data not shown). Therefore post-translational modification of EWS/ATF1 may be important for regulating binding activity as has been shown for EWS/FLI (37) . In direct comparison with ATF1, EWS/ATF1 greatly increases gene expression when measured by reporter assay (26, 38) . The increased activity of EWS/ATF1 is thought to result from either the loss of regulatory elements by truncation of ATF1 or the contribution of the potent EWS transactivation domain (14) . A quantitative comparison of EWS/ATF1 to other intracellular proteins in human tumors has not been previously demonstrated. Since the chimeric protein is not produced in the absence of the translocation between chromosomes 12 and 22, expression levels must be compared with other endogenous protein. As determined by cytogenetic analysis, a single allele of the wild type EWS and ATF1 genes remains intact in SU-CCS-1 cells. Our Western blot experiments indicate that EWS/ATF1 is present in considerable excess to the endogenous levels of ATF1 in the SU-CCS-1 cell line and a CCS tumor (Fig. 1B) . Densitometric analysis indicated that EWS/ATF1 is expressed at a 3.0-fold greater level than ATF1 in the SU-CCS-1 cell line and a 10.6-fold greater level in a CCS tumor. As originally suggested for Ewing's sarcoma, the EWS/ATF1 fusion protein may achieve transformation through both overexpression and strong transcriptional activation capability (39) . Similar explanations have been proposed for alveolar rhabdomyosarcoma associated with translocations of the Pax3 and FKHR protein genes (40) .
EWS/FLI, EWS/ATF1, and other chimeric proteins resulting from specific translocations in leukemias, lymphomas, and sarcomas can be considered true tumor-specific proteins, and the joining region, in particular, could serve as a unique epitope for derivation of antibodies. However, molecular modeling of the EWS/ATF1 chimeric protein suggested that the fusion junction was not an exposed surface and unlikely to be available for binding by antibody. As shown here with mAb5, binding of transcription factors by antibody does not necessarily result in loss of function in vitro. We previously determined that intracellular expression of scFv4 reduced activity of the CRE-containing proliferating cell nuclear antigen promoter by approximately 60%, but no loss of cell viability was seen when compared with controls (18) . Although the proposed mechanism of scFv4 action is through prevention of CRE binding and transcriptional activation by EWS/ATF1, cross-reactivity with ATF1 or even CREB may occur. These transcription factors have been shown to be intimately involved with various proliferative and differentiation processes in many cell types, but their role in the SU-CCS-1 cell line is unknown. As demonstrated by Bar-Eli and associates (41, 42) , inhibition of CREB by a dominant negative mutant leads to loss of viability in melanoma cells. Since a similar phenomenon could be occurring in the SU-CCS-1 cells, the HeLa cell transfections were important in verifying that scFv4 expression was not cytotoxic in cells without EWS/ATF1 (Fig. 5C ). No loss in viability was observed in transfected HeLa cells, and we concluded that scFv4 induced cell death in SU-CCS-1 cells by disruption of EWS/ATF1 activity and not through inhibition of endogenous ATF1 activity.
The process of cell death in SU-CCS-1 cells exposed to scFv4 appears to have occurred through an apoptotic mechanism (25) . However, cell death involves multiple pathways, and ultrastructural studies may be helpful in determining whether evidence of necrosis is present (29) . The finding that 30% of cells exposed to SR␣-Fv4 were apoptotic as compared with controls (p Ͻ 0.005) is comparable to results observed by others (43, 44) in studies of apoptosis.
Disruption of key molecular processes responsible for neoplastic transformation and reversal of malignant phenotypes are important goals in developing new cancer therapeutics (45) . The targeted disruption of EWS/ATF1 activity via the ATF1 epitope of scFv4 reduced SU-CCS-1 cell viability but had little effect on HeLa cells not expressing the oncogenic fusion protein. By demonstrating activity in this tumor cell type, we demonstrate the importance of chimeric proteins with transcriptional activity in maintenance of tumor cell viability. These findings may have broad applications to leukemias, lymphomas, and other sarcomas with characteristic chromosomal translocations involving transcription factors such as the EWS/ FLI-1 in Ewing's sarcoma and Pax3/FKHR in alveolar rhabdomyosarcoma. However, as demonstrated here, the level of the oncogenic EWS/ATF1 protein is higher in primary tumors than in established cell lines, and in vivo studies are needed to determine the therapeutic potential for disruption of fusion protein transcriptional activity by antibodies.
